Anixa Biosciences announced positive early results from its Phase 1 trial of a novel CAR-T therapy targeting ovarian cancer. Multiple patients have survived over one year, including one beyond two years, with no dose-limiting toxicities observed so far. The therapy targets the follicle stimulating hormone receptor (FSHR) on cancer cells and is being tested at Moffitt Cancer Center. These outcomes are notable given the poor prognosis and limited options for recurrent ovarian cancer, and the company plans to continue evaluating this treatment in higher doses.
Anixa Biosciences' ovarian cancer CAR-T trial results provide context for health sector activity on Pluang. As of Oct 01, 2026 19:31 WIB, 60 of 100 health-sector US stocks rose while 33 fell. Moderna (MRNA) traded at USD 186.10 with a 3.36% decline and a typical hold time of 59 days, contrasting with DENTSPLY SIRONA (XRAY) at USD 9.06 gaining 2.26% and a longer hold time of 71 days, and Heron Therapeutics (HRTX) at USD 0.32 up 2.07% but with a shorter hold time of 35 days. Pluang order activity showed a strong sell bias for MRNA and HRTX, but a full buy interest for XRAY.
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
Oklo is developing advanced fast-fission reactors to power future data centers and industrial hubs, aiming to lead in carbon-free energy. Piper Sandler reaffirmed an "Overweight" rating on the stock, reflecting confidence in Oklo's growth prospects. ...
Nike is set to release its quarterly earnings on October 1, 2026, with analysts forecasting an EPS of $0.44 and revenue of $11.32 billion, both down from last year. The company's stock has fallen 80% this year, hitting 13-year lows, reflecting a chal...
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
